[Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori]

Korean J Gastroenterol. 2012 Jun 25;59(6):401-6. doi: 10.4166/kjg.2012.59.6.401.
[Article in Korean]

Abstract

Background/aims: There is increasing need for third-line therapy of Helicobacter pylori due to increasing level of antibiotics resistance. The aim of this study was to compare rifabutin and levofloxacin rescue regimens in patients with first- and second-line Helicobacter pylori eradication failures.

Methods: Patients, in whom a first treatment with proton pump inhibitor-clarithromycin-amoxicillin and a second trial with proton pump inhibitor-bismuth-tetracycline-metronidazole had failed, received treatment with either rifabutin or levofloxacin, plus amoxicillin (1 g twice daily) and standard dose proton pump inhibitor. Eradication rates were confirmed with 13C-urea breath test or rapid urease test 4 weeks after the cessation of therapy.

Results: Eradication rates were 71.4% in the rifabutin group, and 57.1% in the levofloxacin group, respectively. Although there was no significant difference in Helicobacter pylori eradication rates between two groups (p=0.656), rifabutin based regimen showed relatively higher eradication rate.

Conclusions: Helicobacter pylori eradication rates of rifabutin- or levofloxacin-based triple therapy could not achieve enough eradication rate. Further studies would be needed on combination of levofloxacin and rifabutin-based regimen or culture based treatment.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Breath Tests
  • Drug Resistance, Bacterial / drug effects
  • Drug Therapy, Combination
  • Female
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori
  • Humans
  • Levofloxacin*
  • Male
  • Middle Aged
  • Ofloxacin / therapeutic use*
  • Proton Pump Inhibitors / therapeutic use
  • Rifabutin / therapeutic use*
  • Salvage Therapy

Substances

  • Anti-Bacterial Agents
  • Proton Pump Inhibitors
  • Rifabutin
  • Levofloxacin
  • Amoxicillin
  • Ofloxacin